A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type i (IGF-1R) demonstrating unique molecular properties

Journal of Biological Chemistry

Volumn 289, Issue 27, 2014, Pages 18693-18706

  Schanzer, Juergen M ^a   Wartha, Katharina ^a   Croasdale, Rebecca ^a   Moser, Samuel ^b   Künkele, Klaus Peter ^c   Ries, Carola ^a   Scheuer, Werner ^a   Duerr, Harald ^a   Pompiati, Sandra ^a   Pollman, Jan ^a   Stracke, Jan ^a   Lau, Wilma ^a   Ries, Stefan ^a   Brinkmann, Ulrich ^a   Klein, Christian ^b   Umana, Pablo ^b  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

^b Roche Glycart AG   (Switzerland)

^c BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

RATIONAL FUNCTIONS;

CANCER THERAPEUTICS; EPIDERMAL GROWTH FACTOR RECEPTORS; IN-VITRO; INSULIN-LIKE GROWTH FACTOR RECEPTORS; MOLECULAR PROPERTIES; RATIONAL DESIGN; SINGLE CHAINS; TUMOR MODELS;

ANTIBODIES;

EPIDERMAL GROWTH FACTOR RECEPTOR; IMGATUZUMAB; PROTEIN ANTIBODY; R 1507; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; ARTICLE; BINDING SITE; BIOENGINEERING; CONTROLLED STUDY; DIMERIZATION; DRUG POTENCY; ENZYME INHIBITION; FEMALE; GLYCOENGINEERING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LUNG CANCER; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PURIFICATION; SIGNAL TRANSDUCTION;

ANTIBODY ENGINEERING; EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR); GLYCOSYLATION; INSULIN-LIKE GROWTH FACTOR (IGF); TUMOR THERAPY;

ANIMALS; ANTIBODIES, BISPECIFIC; BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN G; MICE; PANCREATIC NEOPLASMS; PROTEIN ENGINEERING; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; PROTEIN TRANSPORT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; SINGLE-CHAIN ANTIBODIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903843654     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.528109     Document Type: Article

References (43)

1. Topp, M. S., Kufer, P., Gökbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H. A., Raff, T., Viardot, A., Schmid, M., Stelljes, M., Schaich, M., Degenhard, E., Köhne-Volland, R., Brüggemann, M., Ottmann, O., Pfeifer, H., Burmeister, T., Nagorsen, D., Schmidt, M., Lutterbuese, R., Reinhardt, C., Baeuerle, P. A., Kneba, M., Einsele, H., Riethmüller, G., Hoelzer, D., Zugmaier, G., and Bargou, R. C. (2011) Targeted therapy with the T-cellengaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J. Clin. Oncol. 29, 2493-2498
2. Wu, C., Ying, H., Grinnell, C., Bryant, S., Miller, R., Clabbers, A., Bose, S., McCarthy, D., Zhu, R. R., Santora, L., Davis-Taber, R., Kunes, Y., Fung, E., Schwartz, A., Sakorafas, P., Gu, J., Tarcsa, E., Murtaza, A., and Ghayur, T. (2007) Simultaneous targeting of multiple disease mediators by a dualvariable- domain immunoglobulin. Nat. Biotechnol. 25, 1290-1297
3. Digiammarino, E. L., Harlan, J. E., Walter, K. A., Ladror, U. S., Edalji, R. P., Hutchins, C. W., Lake, M. R., Greischar, A. J., Liu, J., Ghayur, T., and Jakob, C. G. (2011) Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design. MAbs 3, 487-494
4. Dong, J., Sereno, A., Snyder, W. B., Miller, B. R., Tamraz, S., Doern, A., Favis, M., Wu, X., Tran, H., Langley, E., Joseph, I., Boccia, A., Kelly, R., Wortham, K., Wang, Q., Berquist, L., Huang, F., Gao, S. X., Zhang, Y., Lugovskoy, A., Martin, S., Gouvis, H., Berkowitz, S., Chiang, G., Reff, M., Glaser, S. M., Hariharan, K., and Demarest, S. J. (2011) Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity. J. Biol. Chem. 286, 4703-4717
5. Michaelson, J. S., Demarest, S. J., Miller, B., Amatucci, A., Snyder, W. B., Wu, X., Huang, F., Phan, S., Gao, S., Doern, A., Farrington, G. K., Lugovskoy, A., Joseph, I., Bailly, V., Wang, X., Garber, E., Browning, J., and Glaser, S. M. (2009) Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LT-R. MAbs 1, 128-141
6. Croasdale, R., Wartha, K., Schanzer, J. M., Kuenkele, K. P., Ries, C., Mayer, K., Gassner, C., Wagner, M., Dimoudis, N., Herter, S., Jaeger, C., Ferrara, C., Hoffmann, E., Kling, L., Lau, W., Staack, R. F., Heinrich, J., Scheuer, W., Stracke, J., Gerdes, C., Brinkmann, U., Umana, P., and Klein, C. (2012) Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition. Arch. Biochem. Biophys. 526, 206-218
7. Umaña, P., Jean-Mairet, J., Moudry, R., Amstutz, H., and Bailey, J. E. (1999) Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody- dependent cellular cytotoxic activity. Nat. Biotechnol. 17, 176-180
8. Ferrara, C., Grau, S., Jäger, C., Sondermann, P., Brünker, P., Waldhauer, I., Hennig, M., Ruf, A., Rufer, A. C., Stihle, M., Umaña, P., and Benz, J. (2011) Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FciRIII and antibodies lacking core fucose. Proc. Natl. Acad. Sci. U. S. A. 108, 12669-12674
9. Pollak, M. N., Perdue, J. F., Margolese, R. G., Baer, K., and Richard, M. (1987) Presence of somatomedin receptors on primary human breast and colon carcinomas. Cancer Lett. 38, 223-230
10. Baselga, J., and Mendelsohn, J. (1994) The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res. Treat. 29, 127-138
11. Ludovini, V., Bellezza, G., Pistola, L., Bianconi, F., Di Carlo, L., Sidoni, A., Semeraro, A., Del Sordo, R., Tofanetti, F. R., Mameli, M. G., Daddi, G., Cavaliere, A., Tonato, M., and Crinò, L. (2009) High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann. Oncol. 20, 842-849
12. Bowers, G., Reardon, D., Hewitt, T., Dent, P., Mikkelsen, R. B., Valerie, K., Lammering, G., Amir, C., and Schmidt-Ullrich, R. K. (2001) The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells. Oncogene 20, 1388-1397
13. Ueda, S., Tsuda, H., Sato, K., Takeuchi, H., Shigekawa, T., Matsubara, O., Hiraide, H., and Mochizuki, H. (2006) Alternative tyrosine phosphorylation of signaling kinases according to hormone receptor status in breast cancer overexpressing the insulin-like growth factor receptor type 1. Cancer Sci. 97, 597-604
14. Pollak, M. (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer 8, 915-928
15. Ciardiello, F., and Tortora, G. (2002) Anti-epidermal growth factor receptor drugs in cancer therapy. Expert Opin. Investig. Drugs 11, 755-768
16. Vecchione, L., Vecchione, L., Jacobs, B., Jacobs, B., Normanno, N., Normanno, N., Ciardiello, F., Ciardiello, F., Tejpar, S., Tejpar, S. (2011) EGFRtargeted therapy. Exp. Cell Res. 317, 2765-2771
17. Gerdes, C. A., Nicolini, V. G., Herter, S., van Puijenbroek, E., Lang, S., Roemmele, M., Moessner, E., Freytag, O., Friess, T., Ries, C. H., Bossenmaier, B., Mueller, H. J., and Umaña, P. (2013) GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. Clin. Cancer Res. 19, 1126-1138
18. Paz-Ares, L. G., Gomez-Roca, C., Delord, J. P., Cervantes, A., Markman, B., Corral, J., Soria, J. C., Bergé, Y., Roda, D., Russell-Yarde, F., Hollingsworth, S., Baselga, J., Umana, P., Manenti, L., and Tabernero, J. (2011) Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. J. Clin. Oncol. 29, 3783-3790
19. Pappo, A. S., Patel, S. R., Crowley, J., Reinke, D. K., Kuenkele, K. P., Chawla, S. P., Toner, G. C., Maki, R. G., Meyers, P. A., Chugh, R., Ganjoo, K. N., Schuetze, S. M., Juergens, H., Leahy, M. G., Geoerger, B., Benjamin, R. S., Helman, L. J., and Baker, L. H. (2011) R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J. Clin. Oncol. 29, 4541-4547
20. Ramalingam, S. S., Spigel, D. R., Chen, D., Steins, M. B., Engelman, J. A., Schneider, C. P., Novello, S., Eberhardt, W. E., Crino, L., Habben, K., Liu, L., Jänne, P. A., Brownstein, C. M., and Reck, M. (2011) Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage nonsmall- cell lung cancer. J. Clin. Oncol. 29, 4574-4580
21. Rosen, L. S., Puzanov, I., Friberg, G., Chan, E., Hwang, Y. C., Deng, H., Gilbert, J., Mahalingam, D., McCaffery, I., Michael, S. A., Mita, A. C., Mita, M. M., Mulay, M., Shubhakar, P., Zhu, M., and Sarantopoulos, J. (2012) Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors. Clin. Cancer Res. 18, 3414-3427
22. Weickhardt, A., Doebele, R., Oton, A., Lettieri, J., Maxson, D., Reynolds, M., Brown, A., Jackson, M. K., Dy, G., Adjei, A., Fetterly, G., Lu, X., Franklin, W., Varella-Garcia, M., Hirsch, F. R., Wynes, M. W., Youssoufian, H., Adjei, A., and Camidge, D. R. (2012) A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced nonsmall cell lung cancer. J. Thorac. Oncol. 7, 419-426
23. Chakravarti, A., Loeffler, J. S., and Dyson, N. J. (2002) Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. 62, 200-207
24. Jones, H. E., Goddard, L., Gee, J. M., Hiscox, S., Rubini, M., Barrow, D., Knowlden, J. M., Williams, S., Wakeling, A. E., and Nicholson, R. I. (2004) Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839, Iressa) in human breast and prostate cancer cells. Endocr. Relat. Cancer 11, 793-814
25. Goetsch, L., Gonzalez, A., Leger, O., Beck, A., Pauwels, P. J., Haeuw, J. F., and Corvaia, N. (2005) A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int. J. Cancer 113, 316-328
26. Lu, D., Zhang, H., Koo, H., Tonra, J., Balderes, P., Prewett, M., Corcoran, E., Mangalampalli, V., Bassi, R., Anselma, D., Patel, D., Kang, X., Ludwig, D. L., Hicklin, D. J., Bohlen, P., Witte, L., and Zhu, Z. (2005) A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J. Biol. Chem. 280, 19665-19672
27. Lu, D., Zhang, H., Ludwig, D., Persaud, A., Jimenez, X., Burtrum, D., Balderes, P., Liu, M., Bohlen, P., Witte, L., and Zhu, Z. (2004) Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J. Biol. Chem. 279, 2856-2865
28. Haluska, P., Carboni, J. M., TenEyck, C., Attar, R. M., Hou, X., Yu, C., Sagar, M., Wong, T. W., Gottardis, M. M., and Erlichman, C. (2008) HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol. Cancer Ther. 7, 2589-2598
29. Scartozzi, M., Mandolesi, A., Giampieri, R., Pierantoni, C., Loupakis, F., Zaniboni, A., Galizia, E., Giustini, L., Silva, R. R., Bisonni, R., Berardi, R., Biagetti, S., Menzo, S., Falcone, A., Bearzi, I., and Cascinu, S. (2010) Insulin- like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. Int. J. Cancer 127, 1941-1947
30. Emanuel, S. L., Engle, L. J., Chao, G., Zhu, R. R., Cao, C., Lin, Z., Yamniuk, A. P., Hosbach, J., Brown, J., Fitzpatrick, E., Gokemeijer, J., Morin, P., Morse, B. A., Carvajal, I. M., Fabrizio, D., Wright, M. C., Das Gupta, R., Gosselin, M., Cataldo, D., Ryseck, R. P., Doyle, M. L., Wong, T. W., Camphausen, R. T., Cload, S. T., Marsh, H. N., Gottardis, M. M., and Furfine, E. S. (2011) A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor. MAbs 3, 38-48
31. Hust, M., Jostock, T., Menzel, C., Voedisch, B., Mohr, A., Brenneis, M., Kirsch, M. I., Meier, D., and Dübel, S. (2007) Single chain Fab (scFab) fragment. BMC. Biotechnol. 7, 14
32. Schirrmann, T., Menzel, C., Hust, M., Prilop, J., Jostock, T., and Dübel, S. (2010) Oligomeric forms of single chain immunoglobulin (scIgG). MAbs 2, 73-76
33. Kontermann, R. E., Wing, M. G., and Winter, G. (1997) Complement recruitment using bispecific diabodies. Nat. Biotechnol. 15, 629-631
34. Ridgway, J. B., Presta, L. G., and Carter, P. (1996) "Knobs-into- holes"engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 9, 617-621
35. Klein, C., Sustmann, C., Thomas, M., Stubenrauch, K., Croasdale, R., Schanzer, J., Brinkmann, U., Kettenberger, H., Regula, J. T., and Schaefer, W. (2012) Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. MAbs 4, 653-663
36. Reiter, Y., Brinkmann, U., Kreitman, R. J., Jung, S. H., Lee, B., and Pastan, I. (1994) Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. Biochemistry 33, 5451-5459
37. Reiter, Y., Brinkmann, U., Webber, K. O., Jung, S. H., Lee, B., and Pastan, I. (1994) Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv. Protein Eng. 7, 697-704
38. Schaefer, G., Haber, L., Crocker, L. M., Shia, S., Shao, L., Dowbenko, D., Totpal, K., Wong, A., Lee, C. V., Stawicki, S., Clark, R., Fields, C., Lewis Phillips, G. D., Prell, R. A., Danilenko, D. M., Franke, Y., Stephan, J. P., Hwang, J., Wu, Y., Bostrom, J., Sliwkowski, M. X., Fuh, G., and Eigenbrot, C. (2011) A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 20, 472-486
39. Bostrom, J., Haber, L., Koenig, P., Kelley, R. F., and Fuh, G. (2011) High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity. PLoS One 6, e17887
40. Surati, M., Patel, P., Peterson, A., and Salgia, R. (2011) Role of MetMAb (OA-5D5) in c-MET active lung malignancies. Exp. Opin. Biol. Ther. 11, 1655-1662
41. Schaefer, W., Regula, J. T., Bähner, M., Schanzer, J., Croasdale, R., Dürr, H., Gassner, C., Georges, G., Kettenberger, H., Imhof-Jung, S., Schwaiger, M., Stubenrauch, K. G., Sustmann, C., Thomas, M., Scheuer, W., and Klein, C. (2011) Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc. Natl. Acad. Sci. U. S. A. 108, 11187-11192
42. Lee, H. S., Shu, L., De Pascalis, R., Giuliano, M., Zhu, M., Padlan, E. A., Hand, P. H., Schlom, J., Hong, H. J., and Kashmiri, S. V. (1999) Generation and characterization of a novel single-gene-encoded single-chain immunoglobulin molecule with antigen binding activity and effector functions. Mol. Immunol. 36, 61-71
43. Nagorsen, D., Kufer, P., Baeuerle, P. A., and Bargou, R. (2012) Blinatumomab: a historical perspective. Pharmacol. Ther. 136, 334-342